

This Notice is sent to you as Shareholder of AXA IM Wave Biotech Fund (the "Fund"). It is important and requires your immediate attention. If you are in any doubt as to the action to be taken, you should immediately consult your stockbroker, solicitor or attorney, accountant or other independent financial adviser. If you have sold or otherwise transferred your holding in the Fund, please send at once this document to the stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. Where appropriate, please pass the contents of this communication on to the beneficial investors of the Fund.

This Notice has not been reviewed by the Central Bank of Ireland (the "Central Bank"), and it is possible that changes thereto may be necessary to meet the Central Bank's requirements. The Directors are of the opinion that there is nothing contained in this Notice or in the proposals detailed herein that conflicts with the Central Bank Regulations, the guidance issued by, and the regulations of, the Central Bank. The Directors accept responsibility for the information contained in this Notice.

Capitalised terms used in this notice shall have the same meaning ascribed to them in the latest version of the Prospectus unless the context otherwise requires.

Letter from the Board to the Shareholders of

AXA IM Wave Biotech Fund

AXA IM WORLD ACCESS VEHICLE ICAV

An Umbrella Irish collective asset-management vehicle with limited liability and segregated liability between Funds registered and authorised by the Central Bank of Ireland

Directors: Jean-Louis Laforge (French), Ouajnat Karim (French), Joseph Keane and Kevin O'Brien
Registered Office: 33 Sir John Rogerson's Quay, Dublin 2, Ireland
Registration Number: Ireland, C145706



27th April 2026

Compulsory Redemption Notice to Shareholders in respect of AXA IM Wave Biotech Fund (the “Fund”) and Termination of the Fund

Dear Shareholder

We are writing to inform you that, after careful consideration and with the long-term interests of investors in mind, the Directors of AXA IM World Access Vehicle ICAV (the “**ICAV**”) have resolved that it is in the best interest of the Fund and its investors as a whole to effect a total redemption of all remaining Shares in the Fund as at the Compulsory Redemption Date, in accordance with the Instrument of Incorporation of the ICAV.

Pursuant to clause 13.01 of the Instrument of Incorporation of the ICAV, the Directors may affect a total redemption of Shares of the Fund on a Dealing Day by not less than two nor more than twelve weeks' notice to Shareholders.

The Directors therefore wish to inform you, as a Shareholder in the Fund, of the ICAV's intention to redeem your entire holding in the Fund, with effect from the Dealing Day of 2nd June 2026 (the “**Compulsory Redemption Date**”). If on the Compulsory Redemption Date you remain as a Shareholder in the Fund, all Shares held by you or on your behalf in the Fund which have not been redeemed will be automatically cancelled and redeemed at the Net Asset Value per Share calculated on or with respect to the Compulsory Redemption Date.

If you do not wish to be automatically redeemed on the Compulsory Redemption Date, you can voluntarily redeem your Shares in the Fund at any time up to and including 27th May 2026 (the “**Final Dealing Date**”) in accordance with the Fund's normal redemption procedures as set out in the Fund's Supplement.

However, please note that if a redemption request does not settle by the Compulsory Redemption Date, such voluntary redemption request shall be treated as invalid and such Shares will be compulsorily redeemed on the Compulsory Redemption Date as part of the Fund closure process. **Investors are deemed to have received advance notice of the proposal to close the Fund and may redeem their shares free of charge from 27th April 2026 until the Final Dealing Date. The Fund will also not be processing new subscriptions from 27th April 2026.**

The termination of the Fund will take effect on the Compulsory Redemption Date (the “**Termination Date**”). The decision to terminate the Fund has been prompted by the assets under management of the Fund being at a level where it is no longer commercially viable to manage the Fund. Please note that the final Net Asset Value of the Fund, calculated as at the Termination Date, will reflect standard operating accruals for liabilities and contingencies including for the avoidance of doubt the costs of winding up the Fund.

The ICAV and BNP Paribas Asset Management Europe very much appreciate your investment in the Fund. We believe that in winding down the Fund in this manner you will receive a fair and equitable share of the proceeds of the Fund in which you are invested. We look forward to renewing our investment relationship at a future stage.

AXA IM WORLD ACCESS VEHICLE ICAV

An Umbrella Irish collective asset-management vehicle with limited liability and segregated liability between Funds registered and authorised by the Central Bank of Ireland

Directors: Jean-Louis Laforge (French), Ouajnat Karim (French), Joseph Keane and Kevin O'Brien

Registered Office: 33 Sir John Rogerson's Quay, Dublin 2, Ireland

Registration Number: Ireland, C145706



If you have any queries or need further information, please contact your investor relationship team at BNP Paribas Asset Management Europe.

Yours faithfully

AXA IM World Access Vehicle ICAV

AXA IM WORLD ACCESS VEHICLE ICAV

An Umbrella Irish collective asset-management vehicle with limited liability and segregated liability between Funds registered and authorised by the Central Bank of Ireland

Directors: Jean-Louis Laforge (French), Ouajnat Karim (French), Joseph Keane and Kevin O'Brien
Registered Office: 33 Sir John Rogerson's Quay, Dublin 2, Ireland
Registration Number: Ireland, C145706